Clinical Follow-up of Patients with Behcet Uveitis after Discontinuation of Infliximab Therapy

Kose H. C., Yalcindag N.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.30, sa.1, ss.203-207, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/09273948.2020.1774907
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.203-207
  • Anahtar Kelimeler: Behcet disease, Behcet uveitis, biologic agents, infliximab, treatment, REFRACTORY UVEITIS, DISEASE, EFFICACY, ADALIMUMAB, RECOMMENDATIONS, SAFETY, AZATHIOPRINE, COMBINATION, MANAGEMENT, POSTERIOR
  • Ankara Üniversitesi Adresli: Evet

Özet

Purpose To evaluate the clinical course of patients with Behcet uveitis after discontinuation of infliximab (IFX) therapy. Methods Medical records of eight patients who discontinued treatment between 2010 and 2018 were retrospectively analyzed. The main outcome measures were frequency of uveitis attacks per year, best-corrected visual acuity (BCVA), aqueous flare, foveal thickness and fluorescein angiography (FA) scores before initiation, during treatment and after 6, 12, and 24 months of cessation of the IFX therapy. Results The mean follow-up after withdrawal of infusions was 38.6 +/- 20.4 (12-90) months. Frequency of uveitis attacks, BCVA, aqueous flare, foveal thickness and FA scores were improved significantly after treatment (p< .05). In terms of these parameters, there was no significant difference between the periods of during treatment and after 6, 12, and 24 months of cessation of the IFX therapy. Conclusion IFX therapy might be discontinued safely with an effective inflammation control in patients with Behcet uveitis.